Jonathan Gear: Sure, Shlomo. This is Jonathan Gear. I’ll go ahead and address the first question, and have JC address the second. So, on life sciences, I think what — as others are seeing, we are seeing renewed optimism within our life sciences customers. The commercialization budgets appear to be higher and we’re seeing it kind of across the board, both on large pharma, large biotech and even the small biotech. So, there is renewed optimism coming back into it. That being said, we’re going to want to wait and see in terms of how quickly that converts into really increased demand for our products and services and consulting. So, while we are seeing that certainly in the macro environment, we’ve been cautious about putting that optimism into our guidance in second half. JC, do you want to address Shlomo’s other question?
Jonathan Collins: Yes. And that conservativism around the macro, Shlomo, is the other factor that’s really driving the change in the last year of the guide we gave. So, to your point, we had previously indicated in the 5.5% to 6.5%, or 6% at the midpoint, we’re now in the 4% to 6% range, so we’d have to get to the higher end of that to touch the prior midpoint. That is primarily due to our conservatism around the rate of improvement in the end markets. What could cause us to be to the higher end is faster acceleration, for example, in the commercialization market that, Jonathan, just highlight, a better outlook on the patent renewal front would be another example. So, that is the primary difference in the change between the two outlooks. Thank you.
Mark Donohue: Thank you. Next question, please.
Operator: Next question comes from Andrew Nicholas of William Blair. Please go ahead. Your line is open.
Andrew Nicholas: Thanks, and good morning. I just had a small question on A&G. Jonathan Collins, I think you mentioned it’s the largest transactional quarter. I think, that’s mostly back file sales within Web of Science. But just if you could confirm that’s where the weakness was? And then just any color on the drivers of that? Is that also budget-related cyclical pressures or is there — is it just a timing issue and you’d expect some of that to come back next year? Thank you.
Jonathan Collins: Yeah. Thank you for the question, Andrew. So, as a reminder, we have multiple types of transactional sales within the A&G segment. You touched on one of them where we’re selling the back file of Web of Science, which makes the analytics of the platform much more valuable to the users. Other examples are digital collections, historical collections that we’ve digitized and preserved, and also our books business. So, it’s a combination of those. Q4 usually is the largest quarter for us. What we saw a bit later in the quarter is our customers in that space pausing a bit. What we heard from them is that they want to wait and see on some other spending factors. Most of our customer base is in North America within that part of the business, and their budget years run similar to the school year.
So, their budget year will end in the second quarter. So, we’ll see how that plays out in the coming quarters. But that’s most of the feedback that we heard from that market, and those were the sales that were affected. Thanks, Andrew.
Mark Donohue: Thanks, Andrew.
Jonathan Gear: Great. Thank you, Andrew. I think that was our last question. Just as I wrap, just want to thank everyone for joining our call today and listening with our remarks, engaging with us. As we look forward to next year, again, as we said in the call, 2023 was a foundational year for us as we made the changes that we needed to make to really propel Clarivate. And I look forward to sharing with you over the ensuing quarters coming up of the results of the investments we’re making, innovation as we drive this company to grow. Thank you very much, everyone. Goodbye.
Operator: This concludes today’s call. Thank you for joining. You may now disconnect your line.
